More importantly, the xenograft mouse models further validated the synergistic effects of the combined ECyd and Gefitinib treatment in inhibiting tumor growth in MHCC-97L (Fig. 7E, F), and in Huh-7 cells overexpressing UCK2 (Fig. 7G, H). This evidence concerns the gene UCK2 and neoplasm.